The 36-month beta value for BCLI is also noteworthy at 0.36. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCLI is 71.15M, and at present, short sellers hold a 2.06% of that float. The average trading volume of BCLI on July 24, 2024 was 619.86K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) has seen a decline in its stock price by -6.41 in relation to its previous close of 0.36. However, the company has experienced a -16.85% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-07-08 that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan – LifeSci Advisors Chaim Lebovits – President and Chief Executive Officer Haro Hartounian – Executive Vice President, Chief Operating Officer Bob Dagher – Executive Vice President, Chief Medical Officer Conference Call Participants Jason McCarthy – Maxim Group David Bautz – Zachs Small Cap Research Operator Greetings and welcome to the Brainstorm Cell Therapeutics Mid-Year 2024 Conference Call. At this time, all participants are in a listen-only mode.
BCLI’s Market Performance
Brainstorm Cell Therapeutics, Inc. (BCLI) has seen a -16.85% fall in stock performance for the week, with a -9.19% decline in the past month and a -37.79% plunge in the past quarter. The volatility ratio for the week is 8.75%, and the volatility levels for the past 30 days are at 9.66% for BCLI. The simple moving average for the past 20 days is -9.77% for BCLI’s stock, with a -6.20% simple moving average for the past 200 days.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at -23.24% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.32% of loss for the given period.
Volatility was left at 9.66%, however, over the last 30 days, the volatility rate increased by 8.75%, as shares sank -11.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.05% lower at present.
During the last 5 trading sessions, BCLI fell by -16.85%, which changed the moving average for the period of 200-days by +76.84% in comparison to the 20-day moving average, which settled at $0.3702. In addition, Brainstorm Cell Therapeutics, Inc. saw 23.08% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lindborg Stacy, who purchase 11,500 shares at the price of $1.77 back on Sep 01 ’23. After this action, Lindborg Stacy now owns 181,500 shares of Brainstorm Cell Therapeutics, Inc., valued at $20,402 using the latest closing price.
Stock Fundamentals for BCLI
Current profitability levels for the company are sitting at:
- 260.58 for the present operating margin
- 4.64 for the gross margin
The net margin for Brainstorm Cell Therapeutics, Inc. stands at 215.75. The total capital return value is set at 5.39. Equity return is now at value -1121.89, with -276.90 for asset returns.
Based on Brainstorm Cell Therapeutics, Inc. (BCLI), the company’s capital structure generated -0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -17.43. The debt to equity ratio resting at -0.2. The interest coverage ratio of the stock is -203.93.
Currently, EBITDA for the company is -21.17 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of -376.13. The receivables turnover for the company is -2.77for trailing twelve months and the total asset turnover is -0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.18.
Conclusion
In summary, Brainstorm Cell Therapeutics, Inc. (BCLI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
